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ABSTRACT
In the current modern and global society, social changes are in constant evolution due 
to scientific progress (technology, culture, customs, and hygiene) and produce the 
freedom in individuals to take decisions by themselves or with their doctors toward drug 
consumption. In the arena of marketed drug products which includes society, individual, 
administration, and pharmaceutical industry, the young discipline emerged is social 
pharmacology or sociopharmacology. This science arises from clinical pharmacology, 
and deals with different parameters, which are important in creating knowledge on 
marketed drugs. However, the scope of “social pharmacology” is not covered by 
the so‑called “Phase IV” alone, but it is the science that handles the postmarketing 
knowledge of drugs. The social pharmacology studies the “life cycle” of any marketed 
pharmaceutical product in the social terrain, and evaluates the effects of the real 
environment under circumstances totally different in the drug development process. 
Therefore, there are far‑reaching horizons, plural, and shared predictions among health 
professionals and other, for beneficial use of a drug, toward maximizing the benefits of 
therapy, while minimizing negative social consequences.
KEY WORDS: Clinical pharmacology, drug abuse, Phase IV, post marketing period, 
sociopharmacology
Introduction
Social pharmacology or sociopharmacology, a relatively 
new field in clinical pharmacology, depicts the relationships 
between society and drugs. In its development, the name 
“sociopharmacology” was coined in 1960s when investigators 
realized that it was necessary to assess the effects of drug 
addiction on the mood and behavior of individuals in social 
settings (primarily psychotropic and drug abuse agents).[1‑3] This 
term currently is also used by several researchers restricted 
to drug abuse circumstances, and social behavior impact.[4,5] 
The new approach of social pharmacology and its development 
started in 1980s. During the past few decades, the concept 
of social pharmacology has evolved, and this new discipline 
explores the multiple dimensions of drug use during the 
postmarketing period. Thus, this discipline has expanded 
its horizon and enriched the specialty by incorporating the 
contributions from physicians, pharmacists, nurses, biologists, 
drug epidemiologists, health economists, lawyers, regulators, 
insurance specialists, and communications specialists.[6‑14]
Social pharmacology as a field of health science generates 
knowledge of marketed drugs in the modern world; it refers 
to the evaluation of the social consequences of an individual’s 
exposure to any marketed drug and the factors related to drug 
utilization. This discipline accomplishes the goal of studying 
how to attain knowledge still to be discovered when a drug is 
marketed, because the approval dossier is a tiny part of the 
knowledge that remains to be gathered. The scenario of the 
postmarketing period represents the widest scope of vision 
of medications when they are studied in their current “life 
cycle” in the social habitat, because of their new specific and 
aggressive environment after approval when the strict control 
of the drug development process is no longer in place, or 
due factors related to owners of a drug molecular entity, the 
operations and management by the pharmaceutical industry, 
and the regulators. With regard to public health for the individual 
and society, social pharmacology is perceived as the tip of the 
iceberg of what we could explore to obtain essential data for 
any marketed drug, with the contribution of the heterogeneous 
expertise of health professions. The wide scope of interactions 
among different and extensive vectors which are linked to use 
and benefits of marketed drugs gives this subject huge potential 
in drawing conclusions about risk‑benefit factors, providing 
alert responses, proposing actions for the decision making 
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process, minimizing the negative impact of drugs, as well as 
promoting the proper and efficient use of drugs. Therefore, the 
scope of “social pharmacology” is not covered by the so‑called 
“Phase IV” alone.
The Concept
The researchers in sociology and psychology conceptualized 
social pharmacology to describe the use of psychoactive drugs 
and drug dependence. However, today social pharmacology 
is a vast discipline which gives special emphasis on the 
postmarketing period of drugs and other medicinal products.[12]
Venulet states that social pharmacology is “the ultimate 
step in the natural history of pharmacology in which the 
properties of a drug, its availability, doctor’s prescribing 
patterns, patient’s compliance, etc., combine and interact in a 
manner which determines the final effects of the therapeutic 
efforts”.[6,15] The author (Alloza) defines “social pharmacology as 
a multidisciplinary science and dynamic system that harmonizes 
the critical and influential elements in the use of marketed 
drugs and the interrelationships, among health professionals, 
who directly or indirectly participate in health care, either by 
providing a service or improving drug therapy”.[12]
When focusing on a drug product there is a big difference 
between two situations: The postmarketing setting of a new 
drug is completely different from a drug development stage 
in which rigorous scientific methods are employed. There is 
a great disparity between ideal clinical research conditions 
during the clinical development of the drug and those of its new 
“social habitat” in which it will be exposed for use. External 
circumstances from the point of view of the consumer and 
society have to be taken into consideration because there 
may be differences in the cultural background such as health, 
hygiene, education, ability to understand, and inter‑individual 
response, which creates a pool of inputs for broad horizons 
about drug use, including those social factors, which could 
explain how and why drugs are used outside clinical and 
rational healthcare frameworks. Thus, social pharmacology 
studies the marketed drug in a pluralistic society within a 
multidisciplinary structure. This means including all types of 
professionals who directly or indirectly participate in health care 
and public health, either by providing a service or improving 
drug therapy (information, communication, education, and 
problem solving). Therefore, the list of methodological 
approaches is very extensive (pharmacoepidemiological 
studies in drug surveillance, experimental and observational 
studies [“naturalistic”], drug response variation, outcome 
research, pharmacoeconomic studies, drug‑toxicity evaluation, 
drug regulation evaluation, drug information evaluation, etc.).
The Players
Being an interdisciplinary science, social pharmacology is 
based on complex interrelationships. The major participants 
have been represented through an equilateral triangle, as shown 
in Figure 1. The drug product is represented as the center of 
interest and the three main players (health professionals, health 
authorities, and the pharmaceutical industry) are represented 
at the vertices. The relationship between patient/consumer and 
each of these three vertices occurs in different proportions. 
Many vectors can connect with different components and 
explores options for future research.[12] The pharmaceutical 
industry should play a crucial role in the discovery of new drugs, 
which are medically and socially desirable. Pharmaceutical 
companies are also concerned in this domain for providing 
drug information to doctors as well as to patients. Regulatory 
agencies are involved in drug approval, regulation of the optimal 
level of drug use, application and translation of clinical trials to 
daily therapeutic practice. Health professionals scrutinize the 
rationale for prescription and self‑medication of drugs. The role 
of the health professionals is to identify the social and irrational 
factors governing drug use in order to accustom and rationalize 
drug utilization in daily clinical practice. Drug utilization differs 
according to social characteristics of physicians (sub‑specialty, 
medical education, cultural origin, etc.) or patients (gender, age, 
education, country, job, social status, etc.).[10]
The Variables
Social pharmacology refers to those variables that have 
a profound impact on drug action and the occurrence of 
specific drug effects as recognized and interpreted by the user. 
Previous studies have identified a number of variables (social 
and cultural factors) that influence the nature and occurrence 
of drug effects. Some important and well‑studied variables 
include: Prior mood and body state, physical and social 
setting, symptom sensitivity, knowledge and information, 
body image and awareness, instructions/descriptions prior 
to use, suggestibility, judgments about drug effectiveness, 
personality, collective social knowledge about effects, ethnicity/
social‑cultural background, social interaction dynamics, past 
experiences, social and communication networks, attitudes, 
accessibility and availability of drugs, expectations, health 
provider attitudes and perceptions, environmental cues, group 
behavior/tasks, modeling behaviors, motivations for use, rituals 
of preparation, administration, use, meanings of drug effects, 
value systems/self‑image/lifestyle, labels for describing drug 
effects, external life events, interpretation of drug effects, 
social and legal controls over use, etc. Therefore in a global 
Figure 1: The major players in sociopharmacology (Source: Alloza JL. 
Social Pharmacology: Conceptual remarks. Drug Information Journal 
2004; 38: 321-329)
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conception, the number characteristics for similar variables 
are widely distributed.[5]
Ethnocultural background and Drug Use
Culture is bigger than individual as it is related to mental 
health and substance use on several different strata. Community 
members from different social, ethnic or cultural groups 
may have a greater risk of mental illness or substance abuse 
problems because they may be more exposed to stressful 
conditions like discrimination and isolation. They may have 
divergent viewpoint of health and may face linguistic hurdles 
when they access health or other services.
Sociocultural faith and opinions can frame the approach to and 
behavior regarding drug use and abuse. Culture plays a pivotal role 
in shaping the mind set of individuals about potential problems 
they may face with substance use.[16] For many sociocultural 
bodies, this may grant a protection. For example, the ancient 
Aztecs used to take alcohol before any contact with white colonists 
or immigrants. Their alcohol use was restricted and was only for 
rituals and otherwise use of alcohol was strictly punished under 
penalty of death.[17] Another example is the development of the 
peyote sect in Northern Mexico. Peyote was used in a ceremonial 
backdrop to treat alcohol addiction. This use later became an 
essential part of the native American church, which offered 
important metaphysical treatment for chronic alcoholism.[17] 
Beginning of excessive substance use may occur during periods 
of rapid social change, often among a race who had little access 
to a drug before. Loss of a healthy ethnocultural integrity may 
occur among indigenous populations whose cultures have been 
ruined by the pervasive and abrupt invasion of foreign influence.[18]
Use of psychoactive drugs and substance‑abuse behavior 
can be attributed to genetic and cultural background. The rise 
in drug abuse and addiction is a real concern in India. Recent 
surveys reveal that India has approximately 70 million drug 
addicts. In India, the cultural consciences are changing, the 
underprivileged class is suffering with economic oppression 
while there is an enormous rise in the upper socioeconomic 
class, all of this combined with the declining support of the 
family which is leading to drug abuse and addiction. In India, 
heroin and alcohol are the most abused drugs. However, 
use of drugs like methamphetamine, cocaine, and crack are 
on the rise throughout India. India has witnessed a rise in 
industrialization and urbanization over the past two decades 
leading to large migrations to its cities. This is gradually fading 
traditional culture and changing lifestyle of individual Indians. 
Their new life is making them very susceptible to the stresses 
and strains of modern urban life and to deal with this situation 
a person is turning to drugs for shortterm pleasure. Since, 
there is a rise in drug abuse and addiction in India, the country 
has noticed an increase in transmitted diseases such as HIV, 
tuberculosis, hepatitis B and C, etc., which is a major concern 
of the healthcare sector.[19]
Studies in Social Pharmacology
Different kinds of research questions may arise with 
respect to interrelationships between (a) social and physical 
environmental variables, (b) biochemical and physiological states, 
and (c) pharmacological agents. The majority of studies done in 
sociopharmacology are focused on the effect of pharmacological 
agents on social behaviors. These studies provide organization 
for a diverse and complex field of investigation and suggest the 
kinds of relationships which require investigation. At the same 
time, it has some weaknesses also. Genetic contributions are 
not easily included because phenotypic characters result from 
interactions between genotype and the physical and social 
environments. Further, social behavior is poorly understood as it 
is known that in some circumstances, altering group composition 
alters drug responses in individuals.[3]
The Mission
Government and health authorities can utilize the results 
of social pharmacology studies in decision‑making regarding 
effectiveness, safety, therapeutic efficacy, public health 
indicators, treatment information, and resource allocation. In 
addition, social pharmacology generates hypotheses for new 
studies and enhances quality control of existing procedures.[12] 
Social pharmacology also contributes by making a framework 
for identifying, classifying and analyzing variables and 
understanding the mechanism of drug action in humans. It is 
the fundamental approach for integrating pharmaceutical and 
sociocultural variables to aid in clarifying and understanding 
user‑generated portrayal of their drug experiences, with the 
objective of improving outcomes of drug therapy. The growing 
interest in social pharmacology has given an opportunity for 
pharmaceutical and social science researchers to explore 
the nature and meaning of drug‑taking experiences in an 
integrated manner [Figure 2]. It is also important to teach 
this information to student and practicing pharmacists, 
other health professionals, social scientists and many other 
interested groups who work with drugs and consumers of 
drugs on a regular basis.[5]
The Methods and Examples
Social pharmacology utilizes the following established 
methods for evaluating the use of medicinal products and their 
consequences:
•	 Pharmacoepidemiologic studies: To assess the pattern 
of prescription, consumption, and consequences.[20] 
Figure 2: The mission of social pharmacology (Source: Alloza JL. 
Social Pharmacology: Conceptual remarks. Drug Information Journal 
2004;38:321-329)
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Studies are also done to evaluate quality improvement of 
prescription, dispensing, and follow‑up
•	 Experimental studies and observational studies: To obtain 
baseline data or direct evidence
•	 Naturalistic studies: For clinical evaluation by observing 
subjects in their natural environment[21]
•	 Longitudinal studies: To study the disease process and its 
development and longterm efficacy of the drugs
•	 Postmarketing surveillance studies: To evaluate the safety 
and efficacy of the already marketed drugs as well as 
overuse and misuse of drugs[22]
•	 Drug utilization studies[23]
•	 Clinical audits and other overall assessment of healthcare[24]
•	 Studies on compliance of treatment[25]
•	 Development of treatment formularies and therapeutic 
guidelines: Comparative evaluation is done on the role 
of different criteria in developing the drug formulary 
therapeutic guidelines[26,27]
•	 Assessment of completeness and practical value of product 
package inserts
•	 Pharmacoeconomic studies: To describe and analyze the 
costs of drug therapy to health care systems and society[28]
•	 Research on outcomes, change in quality of life, and patient 
satisfaction[29]
•	 Toxicity evaluation: Evaluation of acute drug toxicity, toxicity 
in special populations, and evaluation of the practical 
information available on the toxicity
•	 Analysis of drug interactions: With food, nutraceuticals, 
probiotics, and all other medicinal products
•	 Studies on the prevention of iatrogeny: Study on potential 
iatrogenic drugs and modes of prevention[30]
•	 Pharmacogenetic studies: To know and explain the 
variability in response due to ethnic variation[31]
•	 Chronopharmacological studies: To adjust the dosage or to 
decide proper dosing time depending on human biological 
rhythms[32]
•	 Studies on special population: Use of drugs by at risk 
populations, especially pregnant women, nursing mothers, 
infants and children, the elderly, patients with chronic 
diseases (e.g., diabetes, renal, hepatic, cardiovascular, and 
psychiatric diseases)[33]
•	 Studies on medication error: To classify and analyze the 
errors in the use, prescription, dispensing, and formulation 
of drugs[34]
•	 Studies of drug compounding[35]
•	 Epidemiological studies on self‑medication, over‑the‑counter 
drugs and use of herbal medicines[36]
•	 Studies of the pattern of use and interactions among 
scientific medicine, quack‑remedies, alternative medicine, 
and placebo effects[37]
•	 Evaluation of interrelationships between patients, 
healthcare professionals and the pharmaceutical industry[38]
•	 Evaluation of the quality of health information and patient 
health education on the appropriate use of medicinal 
products[39]
•	 Evaluation of awareness on health care by the 
media (television, radio, newspaper)[40]
•	 Systematic evaluation of accuracy of information available 
on the internet regarding medicinal products[41]
•	 Assessment of impact on and attitude of the society toward 
new drugs
•	 The study of prescribing “off‑label” use of medicines[42]
•	 Studies on counterfeit drugs
•	 Analysis of inter‑professional communication among 
physicians, clinical pharmacologists, pharmacists, and 
patients[43]
•	 Analysis of promotional drug literature from the 
pharmaceutical industry and its impact[44]
•	 Studies on natural products, banned substances, and doping 
agents
•	 Assessment of implementation and impact of rules and 
regulations made by different health authorities and 
regulatory bodies[45,46]
•	 Analysis of the advantages and disadvantages of electronic 
medical material (prescription, medical records, protocols, 
and information)[47]
•	 Studies on ethical guidelines for the protection of end 
users.[48]
Conclusion
Today social pharmacology is a well‑established discipline, 
included in the academic curriculum of medicine in some 
countries, with a remarkable role in the postmarketing period. 
Postmarketing period is a phase when it is possible to develop 
a large number of pharmacological, epidemiological and public 
health studies, aligned to assess the influence of the drugs over 
the individual and society, to provide vigilant feedbacks, as well 
as to recommend actions for the decision making process, in a 
substantial scientific basis which relates health professionals, 
health managers, administrators and the pharmaceutical industry. 
Thus, sociopharmacology brings together a vast assemblage of 
disciplines connected to evaluation of efficacy, safety, compliance, 
self‑medication, and utilization of economic assets associated with 
the use of pharmaceutical products. To strengthen and enrich the 
discipline, future research should trace how social, economic and 
health policies create conditions that increase harmful drug use, 
as well as develop better ways to provide resources to individuals 
and communities to reduce harmful drug use.
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